From 7f1d866001cb5999ac076709b40a7dc56a461696 Mon Sep 17 00:00:00 2001 From: Mellisa Aguilar Date: Wed, 30 Sep 2026 18:24:17 +0800 Subject: [PATCH] Add FDA Approves Exenatide for Children and Teens with Type 2 Diabetes --- ...xenatide-for-Children-and-Teens-with-Type-2-Diabetes.md | 7 +++++++ 1 file changed, 7 insertions(+) create mode 100644 FDA-Approves-Exenatide-for-Children-and-Teens-with-Type-2-Diabetes.md diff --git a/FDA-Approves-Exenatide-for-Children-and-Teens-with-Type-2-Diabetes.md b/FDA-Approves-Exenatide-for-Children-and-Teens-with-Type-2-Diabetes.md new file mode 100644 index 0000000..5224334 --- /dev/null +++ b/FDA-Approves-Exenatide-for-Children-and-Teens-with-Type-2-Diabetes.md @@ -0,0 +1,7 @@ +
The FDA recently approved BYDUREON BCise (an extended-release version of the GLP-1 drug, exenatide) for teens with type 2 diabetes. Recently published data shows disturbingly high rates and serious diabetes complications in people who develop type 2 diabetes at a young age suggesting the need for aggressive early treatment and more treatment options. On July 23rd, the FDA approved the [drug BYDUREON](https://www.medcheck-up.com/?s=drug%20BYDUREON) BCise (exenatide), a GLP-1 receptor agonist, for teens ages 10-17 with type 2 diabetes. This drug is a once-weekly injection that can help people manage their glucose levels coupled with changes in their lifestyle (diet and exercise). The approval of BYDUREON BCise comes after encouraging results from a clinical trial called BCB114, [MedicGLP](http://cleanhasugu.co.kr/bbs/board.php?bo_table=b0401&wr_id=4690) which examined the safety of the drug in the age group between 10-17 years old. BYDUREON BCise has been approved in the US for adults with type 2 diabetes for over 15 years, and now, with the results from this clinical trial, BYDUREON BCise has been deemed safe for teens with type 2 diabetes as well.
+ +
Results from the BCB114 trial showed a 0.4 percentage point decrease in A1C when using BYDUREON BCise compared to a 0.5 percentage point increase in A1C among those taking the placebo drug. Given how limited the treatment options are for this population (only three other non-insulin medications are currently approved), the approval of an additional medication is exciting, especially given that this medication could also potentially have positive effects on weight management and heart health. It adds to the options for patients who cannot attain glucose control on metformin alone. Dr. Philip Zeitler, Section Head of Endocrinology and Medical Director at Children’s Hospital of Colorado Clinical and Translational Research Center, shared this optimism on the future of medications for pediatric type 2 diabetes. According to Dr. Zeitler, "exenatide was first in its class of GLP-1 receptor agonists, but was originally given by injection twice a day, which led to challenges of treatment adherence.
+ +
BYDUREON BCise is a type of drug called a glucagon-like peptide (or GLP-1) receptor agonist. GLP-1 receptor agonists work by supporting the action of a hormone called GLP-1 that stimulates the release of insulin in your body. Some GLP-1 receptor agonists have been shown to help with [weight management formula](https://www.speedway-world.pl/forum/member.php?action=profile&uid=537785) management in people with both diabetes and obesity and can also lower the risk of heart disease. These effects have become increasingly important to address in the youth population with type 2 diabetes. Results from a recent clinical study called TODAY2 show a decrease in blood glucose control in youths with type 2 over the last 15 years. Additionally, the study emphasized the need for heart health benefits in this population, with over two thirds of study participants having high blood pressure and over half of the participants showing high fat levels in the blood and early warning signs of amputation. As previously mentioned, the only non-insulin medications approved for teens with type 2 diabetes prior to BYDUREON BCise included metformin and Saxenda and Victoza (both GLP-1 receptor agonists). Compared to the wide variety of medications available for adults, only three have been approved in teens, despite the increasing prevalence of type 2 diabetes in this age group over the last 20 years along with alarming increases in childhood obesity across the United States. Given these trends and the alarming results of the TODAY2 study, it is now more important than ever that this population has multiple options for diabetes management. "We have seen a concerning rise in the number of children who develop type 2 diabetes," said Dr. Chao. "Diabetes-related complications develop earlier in people diagnosed in childhood compared to those diagnosed in adulthood. These complication rates are also higher when compared to children with similar duration of type 1 diabetes. Having more treatment options allows us to personalize treatment plans.
+ +
Science continues to prove that the old adage "you are what you eat" is profoundly true. This is because you have trillions of microorganisms living in your gut, which are directly responsible for nearly every aspect of your health. These microbes make up what’s called your "gut microbiota." They are especially influential in determining your likelihood of gaining excessive weight, becoming obese, and developing obesity-related diseases like diabetes, heart disease, and premature death. The gut microbiome (the expressed genes of your gut microbiota) plays a major role in your metabolism through energy production, storage, and expenditure. So, it’s no surprise that science has found a strong connection between gut microbiome imbalance and metabolic syndrome. Yikes! If you have the wrong mix of microbes, it could be making it tough for you to get your health on track! Did you know: Scientists can actually look at your gut microbiome composition and tell with 90% accuracy if you are obese or lean. That’s pretty impressive, isn’t it?
\ No newline at end of file